These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 4155865)
41. Assessment of bacteriocin production by clinical Pseudomonas aeruginosa isolates and their potential as therapeutic agents. Charkhian H; Soleimannezhadbari E; Bodaqlouei A; Lotfollahi L; Lotfi H; Yousefi N; Shojadel E; Gholinejad Z Microb Cell Fact; 2024 Jun; 23(1):175. PubMed ID: 38872163 [TBL] [Abstract][Full Text] [Related]
42. Antibacterial action of complexing compounds. II. Influence of disodium ethylendiaminetetraacetate (NA2EDTA) on experimental infection with Pseudomonas aeruginosa in mice. Rogala D; Kapp-Burzyńska Z; Komider S Arch Immunol Ther Exp (Warsz); 1974; 22(6):791-6. PubMed ID: 4217611 [No Abstract] [Full Text] [Related]
43. Impact of FiuA Outer Membrane Receptor Polymorphism on the Resistance of Latino L; Patin D; Chérier D; Touzé T; Pourcel C; Barreteau H; Mengin-Lecreulx D J Bacteriol; 2019 Jul; 201(13):. PubMed ID: 30988031 [TBL] [Abstract][Full Text] [Related]
44. [Characteristics and epidemiological significance of the Pseudomonas aeruginosa strains isolated in Rumania from sporadic cases and nocosomial infections]. Meitert E; Meitert T Arch Roum Pathol Exp Microbiol; 1972 Sep; 31(3):443-8. PubMed ID: 4198514 [No Abstract] [Full Text] [Related]
45. [Typization of Pseudomonas aeruginosa by means of pyocins (pyocinogenotypie) (author's transl)]. Zahradnický J Cesk Epidemiol Mikrobiol Imunol; 1979 Sep; 28(5):276-83. PubMed ID: 161515 [No Abstract] [Full Text] [Related]
46. Antimicrobial activity of fosfomycin against multidrug-resistant Pseudomonas aeruginosa in vitro. Kobayashi Y; Sumitani Y; Sugita K; Aikawa N Int J Antimicrob Agents; 2007 Dec; 30(6):563-4. PubMed ID: 17900870 [No Abstract] [Full Text] [Related]
47. Pyocin sensitivity of pseudomonas aeruginosa pretreated with antibiotics. Stevens GS; Ottolenghi AC Can J Microbiol; 1977 May; 23(5):583-8. PubMed ID: 194663 [TBL] [Abstract][Full Text] [Related]
48. Induction of resistance to fluoroquinolones in clinical and environmental isolates of Pseudomonas aeruginosa. Prasad SV; Ballal M; Shivananda PG Indian J Pathol Microbiol; 2007 Jan; 50(1):94-6. PubMed ID: 17474274 [TBL] [Abstract][Full Text] [Related]
57. Typing of non-serogroupable Neisseria meningitidis by means of sensitivity to R-type pyocines of Pseudomonas aeruginosa. Blackwell CC; Law JA J Infect; 1981 Dec; 3(4):370-8. PubMed ID: 6821098 [No Abstract] [Full Text] [Related]
58. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program. Turner PJ Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798 [TBL] [Abstract][Full Text] [Related]
59. A Colicin M-Type Bacteriocin from Pseudomonas aeruginosa Targeting the HxuC Heme Receptor Requires a Novel Immunity Partner. Ghequire MGK; Öztürk B Appl Environ Microbiol; 2018 Sep; 84(18):. PubMed ID: 29980560 [TBL] [Abstract][Full Text] [Related]
60. Comparative study on R-type pyocins of Pseudomonas aeruginosa. Ohsumi M; Shinomiya T; Kageyama M J Biochem; 1980 Apr; 87(4):1119-25. PubMed ID: 6771248 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]